Bicara Therapeutics Inc. (BCAX) Forward P/S Multiple

Corporate emblem and logo of Bicara Bio (BCAX)

Bicara Therapeutics Inc. (BCAX) is executing its plan to bring bispecific antibodies to market for the treatment of head and neck tumors. The company's forward P/S valuation reflects the market reaction to these achievements, with the mark indicating the current valuation level. Business prospects rely on the flagship product's superiority over standards of care and the successful completion of the final clinical trial stages for ficerafusp alfa.

Bicara Therapeutics - BCAX Forward P/S Multiple (period 07/04/2022 - 11/15/2026)

Metric breakdowns and analytics for Bicara Therapeutics (BCAX)

- current price and projected stock value:
Summary company analysis:Bicara Therapeutics (BCAX)
Product sample of bicara.com

To objectively value Bicara Therapeutics Inc. (BCAX), a manager must compare current market value with expected revenues. This metric is calculated as the ratio of market capitalization to projected revenue, determining the extent to which the asset is overbought. By analyzing the forward P/S ratio, an investor can identify growth potential or the risk of a correction. For a brand in the targeted oncology therapy sector, this is critical when assessing the cost of developing innovative antibodies.

Competing companies

Forward P/S Multiple ONC (BeiGene Oncology)|Forward P/S Multiple Halozyme Corp HALO|RVMD: Forward Price-to-Revenue Multiple|Ascentage Pharma Group (AAPG) - Forward Price-to-Revenue Multiple|CG Oncology Therapeutics (CGON) - Price-to-Projected Revenue Ratio|Projected Price to Revenue UroGen Pharma URGN|Price-to-Projected Revenue Ratio personalis.com|Forward Price-to-Revenue Multiple Erasca Corp (ERAS)|Forward Price-to-Revenue Multiple DCTH (Delcath)|Market Cap to Expected Sales Ratio Y-mAbs Therapeutics, Inc.|Forward P/S Multiple AURA (Aura Biosciences Inc)|Forward Price to Sales CADL|ARAY: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue CTOR|Price-to-Projected Revenue Ratio TuHURA Biosciences Inc.|TARA: Forward Price to Sales|Price-to-Projected Revenue Ratio Fate Therapeutics (FATE)|Market Cap to Expected Sales Ratio Aadi Bioscience|Price-to-Projected Revenue Ratio TScan Therapeutics Inc TCRX|CSBR: Market Cap to Projected Revenue|XBIT: Forward Price-to-Revenue Multiple|Forward Price to Sales CVM (cel-sci.com)|OSTX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Forward P/S Multiple|Market Cap to Projected Revenue ANL (Adlai Nortye)|Price-to-Projected Revenue Ratio Veru Pharma (VERU)|Forward P/S Multiple Tempest Tx (TPST)|Price-to-Projected Revenue Ratio xiliotx.com XLO|Enochian BioSciences - Price-to-Projected Revenue Ratio|Mural Oncology - Forward P/S Multiple|KAPA - Forward P/S Multiple|OnKure Therapeutics Inc (OKUR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple CytoMed|Price-to-Projected Revenue Ratio curis.com|Forward Price-to-Revenue Multiple Apollomics, Inc. (APLM)|Forward P/S Multiple THAR|Advanced Biomed Corp - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Genprex GNPX|Market Cap to Expected Sales Ratio Calidi Bio (CLDI)|sunshinebiopharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio xeneticbio.com|salariuspharma.com (SLRX) - Price-to-Projected Revenue Ratio|Purple Biotech Ltd. - Forward Price to Sales|Price-to-Projected Revenue Ratio AON|Forward P/S Multiple BeiGene Ltd.|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|Forward Price-to-Revenue Multiple Elevation Oncology, Inc. ELEV|Forward P/S Multiple ICAD (iCAD Inc.)|IKNA - Forward Price-to-Revenue Multiple|NTBL: Forward Price-to-Revenue Multiple|viracta.com (VIRX) - Forward Price-to-Revenue Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Corp (NAYA) - Forward P/S Multiple|AAPGV (Ascentage) - Forward P/S Multiple